Summaries & Associations of Study Results
TR-491 Methyleugenol
Target Organs and Levels of Evidence
NTP Technical Report Number 491
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| METHYLEUGENOL 93-15-2 |
10/30/98 | FLAVORING AGENT IN FOODS AND BEVERAGES; AS A FRAGRANCE IN COSMETICS; AS AN INSE >>CT ATTRACTANT IN ERADICATION PROGRAMS AND AS AN ANESTHETIC IN RODENTS. | Gavage R&M: 0, 37, 75, OR 150 MG/KG; 50/SEX/SPECIES/GROUP | Battelle Columbus Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | LIVER: ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50 | |||
| GLANDULAR STOMACH: BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50 | ||||
| KIDNEY TUBULAR CELL: ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50 | ||||
| MESOTHELIUM (ABDOMINAL CAVITY/TUNICA VAGINALIS): MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50 | ||||
| MAMMARY GLAND: FIBROADENOMA 5/50 5/50 15/50 13/50 6/50 | ||||
| SKIN: FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA; CYSTIC DEGENERATION | |||
| GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY | ||||
| FR: CLEAR EVIDENCE | LIVER: ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50 | |||
| GLANDULAR STOMACH: BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50 | ||||
| MAY HAVE BEEN RELATED: | FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCI, MIXED CELL FOCI; HEPATOCYTE HYPERTROPHY; OVAL CELL HYPERPLASIA, BILE DUCT HYPERPLASIA; CYSTIC DEGENERATION | |||
| GLANDULAR STOMACH: NEUROENDOCRINE CELL HYPERPLASIA; ATROPHY | ||||
| MM: CLEAR EVIDENCE | LIVER: ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50 | |||
| GLANDULAR STOMACH: MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50 | ||||
| NON-NEOPLASTIC LESIONS: | LIVER: EOSINOPHILIC FOCI; OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY | |||
| GLANDULAR STOMACH: ATROPHY; HYPERPLASIA; ECTASIA | ||||
| FM: CLEAR EVIDENCE | LIVER: ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: OVAL CELL HYPERPLASIA; HEPATOCYTE HYPERTROPHY; HEPATOCYTE NECROSIS; HEMATOPOIETIC CELL PROLIFERATION; BILE DUCT HYPERPLASIA; HEMOSIDERIN PIGMENTATION | |||
| GRANDULAR STOMACH: ATROPHY; ECTASIA | ||||
Web page last updated on February 10, 2006
